Chondrosarcomas are the second most common primary bone malignancy. Chondrosarcomas are characterized by the production of cartilaginous matrix and are generally resistant to radiation and chemotherapy and the outcomes are overall poor. Hence, there is strong interest in determining mechanisms of cancer aggressiveness and therapeutic resistance in chondrosarcomas. There are metabolic alterations in chondrosarcoma that are linked to the epigenetic state and tumor microenvironment that drive treatment resistance. This review focuses on metabolic changes in chondrosarcoma, and the relationship between signaling via isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2), hedgehog, PI3K-mTOR-AKT, and SRC, as well as histone acetylation and angiogenesis. Also, potential treatment strategies targeting metabolism will be discussed including potential synergy with immunotherapies.
Recommended CitationMicaily, Ida; Roche, Megan E; Ibrahim, Mohammad Y; Martinez-Outshoorn, Ubaldo E.; and Mallick, Atrayee Basu, "Metabolic Pathways and Targets in Chondrosarcoma" (2021). Department of Medical Oncology Faculty Papers. Paper 169.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.